<DOC>
	<DOCNO>NCT00699049</DOCNO>
	<brief_summary>The purpose study explore additional benefit solifenacin 12-week treatment , compare alpha blocker monotherapy men residual OAB symptom .</brief_summary>
	<brief_title>A Study Comparing Efficacy Alpha Blocker Versus Alpha Blocker Plus Solifenacin Men With Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>Adrenergic alpha-Antagonists</mesh_term>
	<criteria>Persistent symptom OAB verify 3 day void diary , define : symptom urinary urgency ( define level &gt; =3 5 point urgency scale ) least two episode per 24 hour symptom urinary frequency ( &gt; 8 micturition per 24 hour ) On stable dose tamsulosin least 1 month Previous history acute urinary retention Patients baseline postvoid residual ( PVR ) exceed 50 % voided urine volume Any condition contraindication anticholinergic treatment , include uncontrolled narrowangled glaucoma , urinary retention gastric retention Symptomatic acute urinary tract infection ( UTI ) screen period Treatment within 14 day precede randomization , expect initiate treatment study anticholinergic drug drug treatment overactive bladder A 5alpha reductase inhibitor start less 3 month prior screen Patients previous urethral , prostate bladder neck surgery</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Alpha blocker</keyword>
	<keyword>Tamsulosin</keyword>
	<keyword>Solifenacin</keyword>
	<keyword>Overactive Bladder</keyword>
	<keyword>Urgency incontinence</keyword>
</DOC>